BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

181 related articles for article (PubMed ID: 25868579)

  • 1. Gemcitabine/dexamethasone/cisplatin vs cytarabine/dexamethasone/cisplatin for relapsed or refractory aggressive-histology lymphoma: cost-utility analysis of NCIC CTG LY.12.
    Cheung MC; Hay AE; Crump M; Imrie KR; Song Y; Hassan S; Risebrough N; Sussman J; Couban S; MacDonald D; Kukreti V; Kouroukis CT; Baetz T; Szwajcer D; Desjardins P; Shepherd L; Meyer RM; Le A; Chen BE; Mittmann N;
    J Natl Cancer Inst; 2015 Jul; 107(7):. PubMed ID: 25868579
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Randomized comparison of gemcitabine, dexamethasone, and cisplatin versus dexamethasone, cytarabine, and cisplatin chemotherapy before autologous stem-cell transplantation for relapsed and refractory aggressive lymphomas: NCIC-CTG LY.12.
    Crump M; Kuruvilla J; Couban S; MacDonald DA; Kukreti V; Kouroukis CT; Rubinger M; Buckstein R; Imrie KR; Federico M; Di Renzo N; Howson-Jan K; Baetz T; Kaizer L; Voralia M; Olney HJ; Turner AR; Sussman J; Hay AE; Djurfeldt MS; Meyer RM; Chen BE; Shepherd LE
    J Clin Oncol; 2014 Nov; 32(31):3490-6. PubMed ID: 25267740
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Salvage chemotherapy and autologous stem cell transplantation for transformed indolent lymphoma: a subset analysis of NCIC CTG LY12.
    Kuruvilla J; MacDonald DA; Kouroukis CT; Cheung M; Olney HJ; Turner AR; Anglin P; Seftel M; Ismail WS; Luminari S; Couban S; Baetz T; Meyer RM; Hay AE; Shepherd L; Djurfeldt MS; Alamoudi S; Chen BE; Crump M
    Blood; 2015 Aug; 126(6):733-8. PubMed ID: 26109202
    [TBL] [Abstract][Full Text] [Related]  

  • 4. [Outpatient reinduction therapy with gemcitabine, dexamethasone, Cisplatin (GDP) for patients with relapsed and refractory lymphoma].
    Aota Y; Tanaka M; Watanabe N; Tomomatu J; Gotoh A; Komatu N
    Gan To Kagaku Ryoho; 2015 Jan; 42(1):51-5. PubMed ID: 25596679
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Gemcitabine, dexamethasone and cisplatin (GDP) is an effective and well-tolerated mobilization regimen for relapsed and refractory lymphoma: a single center experience.
    Batgi H; Başcı S; Dal MS; Kızıl Çakar M; Uncu Ulu B; Yiğenoğlu TN; Özcan N; Kılınç A; Merdin A; Yıldız J; Bakırtaş M; Şahin D; Darçın T; İskender D; Baysal NA; Altuntaş F
    Turk J Med Sci; 2021 Apr; 51(2):685-692. PubMed ID: 33237657
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Economic analysis of a randomized phase III trial of gemcitabine plus vinorelbine compared with cisplatin plus vinorelbine or cisplatin plus gemcitabine for advanced non-small-cell lung cancer (Italian GEMVIN3/NCIC CTG BR14 trial).
    Reaume MN; Leighl NB; Mittmann N; Coyle D; Hirsh V; Seymour L; Tu D; Shepherd FA; Graham B; Gridelli C; Perrone F; Di Maio M; Bradbury PA; Evans WK
    Lung Cancer; 2013 Oct; 82(1):115-20. PubMed ID: 23962449
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Gemcitabine, dexamethasone, and cisplatin in patients with recurrent or refractory aggressive histology B-cell non-Hodgkin lymphoma: a Phase II study by the National Cancer Institute of Canada Clinical Trials Group (NCIC-CTG).
    Crump M; Baetz T; Couban S; Belch A; Marcellus D; Howson-Jan K; Imrie K; Myers R; Adams G; Ding K; Paul N; Shepherd L; Iglesias J; Meyer R
    Cancer; 2004 Oct; 101(8):1835-42. PubMed ID: 15386331
    [TBL] [Abstract][Full Text] [Related]  

  • 8. The economic impact of the transition from branded to generic oncology drugs.
    Cheung WY; Kornelsen EA; Mittmann N; Leighl NB; Cheung M; Chan KK; Bradbury PA; Ng RCH; Chen BE; Ding K; Pater JL; Tu D; Hay AE
    Curr Oncol; 2019 Apr; 26(2):89-93. PubMed ID: 31043808
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Similar response rates and superior early progression-free survival with gemcitabine, dexamethasone, and cisplatin salvage therapy compared with carmustine, etoposide, cytarabine, and melphalan salvage therapy prior to autologous stem cell transplantation for recurrent or refractory Hodgkin lymphoma.
    Kuruvilla J; Nagy T; Pintilie M; Tsang R; Keating A; Crump M
    Cancer; 2006 Jan; 106(2):353-60. PubMed ID: 16329112
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Time-intensified dexamethasone/cisplatin/cytarabine: an effective salvage therapy with low toxicity in patients with relapsed and refractory Hodgkin's disease.
    Josting A; Rudolph C; Reiser M; Mapara M; Sieber M; Kirchner HH; Dörken B; Hossfeld DK; Diehl V; Engert A;
    Ann Oncol; 2002 Oct; 13(10):1628-35. PubMed ID: 12377653
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Salvage chemotherapy of gemcitabine, dexamethasone, and cisplatin (GDP) for patients with relapsed or refractory peripheral T-cell lymphomas: a consortium for improving survival of lymphoma (CISL) trial.
    Park BB; Kim WS; Suh C; Shin DY; Kim JA; Kim HG; Lee WS
    Ann Hematol; 2015 Nov; 94(11):1845-51. PubMed ID: 26251158
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Treatment outcomes for older patients with relapsed/refractory aggressive lymphoma receiving salvage chemotherapy and autologous stem cell transplantation are similar to younger patients: a subgroup analysis from the phase III CCTG LY.12 trial.
    Davison K; Chen BE; Kukreti V; Couban S; Benger A; Berinstein NL; Kaizer L; Desjardins P; Mangel J; Zhu L; Djurfeldt MS; Hay AE; Shepherd LE; Crump M
    Ann Oncol; 2017 Mar; 28(3):622-627. PubMed ID: 27993811
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Gemcitabine, cisplatin, and dexamethasone and ifosfamide, carboplatin, and etoposide regimens have similar efficacy as salvage treatment for relapsed/refractory aggressive lymphoma: A retrospectively comparative study.
    Mi M; Zhang C; Liu Z; Wang Y; Li J; Zhang L
    Medicine (Baltimore); 2020 Dec; 99(49):e23412. PubMed ID: 33285732
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Rituximab, gemcitabine, cisplatin, and dexamethasone in patients with refractory or relapsed aggressive B-cell lymphoma.
    Hou Y; Wang HQ; Ba Y
    Med Oncol; 2012 Dec; 29(4):2409-16. PubMed ID: 22476761
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Comparison of ICE (ifosfamide-carboplatin-etoposide) versus DHAP (cytosine arabinoside-cisplatin-dexamethasone) as salvage chemotherapy in patients with relapsed or refractory lymphoma.
    Abali H; Urün Y; Oksüzoğlu B; Budakoğlu B; Yildirim N; Güler T; Ozet G; Zengin N
    Cancer Invest; 2008 May; 26(4):401-6. PubMed ID: 18443961
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Cost-effectiveness analysis of gemcitabine plus cisplatin versus docetaxel, cisplatin and fluorouracil for induction chemotherapy of locoregionally advanced nasopharyngeal carcinoma.
    Wu Q; Liao W; Huang J; Zhang P; Zhang N; Li Q
    Oral Oncol; 2020 Apr; 103():104588. PubMed ID: 32070923
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Rituximab improves the treatment results of DHAP-VIM-DHAP and ASCT in relapsed/progressive aggressive CD20+ NHL: a prospective randomized HOVON trial.
    Vellenga E; van Putten WL; van 't Veer MB; Zijlstra JM; Fibbe WE; van Oers MH; Verdonck LF; Wijermans PW; van Imhoff GW; Lugtenburg PJ; Huijgens PC
    Blood; 2008 Jan; 111(2):537-43. PubMed ID: 17971487
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Mitoxantrone-DHAP with GM-CSF: an active but myelosuppressive salvage therapy for relapsed/refractory aggressive non-Hodgkin's lymphoma.
    Haq R; Sawka CA; Franssen E; Berinstein NL
    Leuk Lymphoma; 1999 Nov; 35(5-6):527-36. PubMed ID: 10609790
    [TBL] [Abstract][Full Text] [Related]  

  • 19. High-dose infusional ifosfamide, etoposide plus methylprednisolone followed by dexamethasone, high-dose ara-C and cisplatinum and autologous stem cell transplantation for refractory or relapsed aggressive non-Hodgkin's lymphoma.
    Salar A; Martino R; Perea G; Ribera JM; López-Guillermo A; Guardia R; Escoda L; Altés A; Sierra J; Montserrat E
    Haematologica; 2002 Oct; 87(10):1028-35. PubMed ID: 12368156
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Gemcitabine, dexamethasone, and cisplatin (GDP) as salvage chemotherapy for patients with relapsed or refractory peripheral T cell lymphoma-not otherwise specified.
    Qi F; Dong M; He X; Li Y; Wang W; Liu P; Yang J; Gui L; Zhang C; Yang S; Zhou S; Shi Y
    Ann Hematol; 2017 Feb; 96(2):245-251. PubMed ID: 27858107
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.